D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
ClinicalTrials.gov Identifier:
NCT01851265 http://clinicaltrials.gov/ct2/show/N...o_unk=Y&rank=4 This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating 3 different breakfasts (high calorie, regular and none). In Part B Patients can take olaparib capsules daily and study assessments will be recorded for 6 months (minimum). Treatment can continue for as long as the patient is benefitting. Throughout the study patients will be monitored for any side effects. |
All times are GMT -7. The time now is 10:44 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021